Report cover image

Global Targeted Therapy For Kidney Disease Market Growth (Status and Outlook) 2025-2031

Publisher LP Information, Inc.
Published Jun 13, 2025
Length 106 Pages
SKU # LPI20086366

Description

The global Targeted Therapy For Kidney Disease market size is predicted to grow from US$ 125 million in 2025 to US$ 173 million in 2031; it is expected to grow at a CAGR of 5.5% from 2025 to 2031.

Targeted therapy for kidney disease is a treatment method that intervenes by targeting specific molecules or pathological mechanisms of kidney disease. This therapy selectively targets pathogenic factors such as immune system abnormalities, inflammatory responses or cell damage according to different types of kidney disease, such as diabetic nephropathy and tubulointerstitial disease, to reduce side effects and improve treatment effects. Targeted therapy usually includes small molecule drugs, monoclonal antibodies, etc., which can effectively delay disease progression and improve renal function, and is an important direction for modern kidney disease treatment.

United States market for Targeted Therapy For Kidney Disease is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Targeted Therapy For Kidney Disease is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Targeted Therapy For Kidney Disease is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Targeted Therapy For Kidney Disease players cover AstraZeneca, Pfizer, Amgen, FibroGen, GlaxoSmithkline, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Targeted Therapy For Kidney Disease Industry Forecast” looks at past sales and reviews total world Targeted Therapy For Kidney Disease sales in 2024, providing a comprehensive analysis by region and market sector of projected Targeted Therapy For Kidney Disease sales for 2025 through 2031. With Targeted Therapy For Kidney Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Therapy For Kidney Disease industry.

This Insight Report provides a comprehensive analysis of the global Targeted Therapy For Kidney Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Therapy For Kidney Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Therapy For Kidney Disease market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Therapy For Kidney Disease and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Therapy For Kidney Disease.

This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Therapy For Kidney Disease market by product type, application, key players and key regions and countries.

Segmentation by Type:
ACE Inhibitors
Calcium Channel Blocker
Beta Blockers
Diuretics
Others

Segmentation by Application:
Hospital
Pharmacy

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Pfizer
Amgen
FibroGen
GlaxoSmithkline
AbbVie
Akebia Therapeutics
Teva Pharmaceutical Industries
Johnson & Johnson
Roche
MicuRx
Everest Medicines
RemeGen

Please note: The report will take approximately 2 business days to prepare and deliver.

Table of Contents

106 Pages
*This is a tentative TOC and the final deliverable is subject to change.*
1 Scope of the Report
2 Executive Summary
3 Targeted Therapy For Kidney Disease Market Size by Player
4 Targeted Therapy For Kidney Disease by Region
5 Americas
6 APAC
7 Europe
8 Middle East & Africa
9 Market Drivers, Challenges and Trends
10 Global Targeted Therapy For Kidney Disease Market Forecast
11 Key Players Analysis
12 Research Findings and Conclusion

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us